Paves way for developpment of this novel drug
Transgene Biotek announced that the Company's novel molecule miRNA 101 for therapy against liver cancer has been allowed issuance of a USA patent after the prosecution on the merits have been closed.This invention by Transgene is targeted for the treatment of hepato-cellular cancer (HCC) based on micro RNA 101 delivered by the Company's novel and patented Adeno-associated virus 8 serotype (AVV-8).
This granting of a USA patent is a significant step in moving ahead with the development of this novel drug.
Powered by Capital Market - Live News
